According to the researchers, the new drug surpasses widespread treatment of dysbacteriosis. These results were obtained jointly with сolleagues from A.N.Nesmeyanov Institute of Organoelement Compounds of Russian Academy of Sciences

The advantage of the new product is in high biodiversity of bifidobacterium and lactobacillus including Lactobacillus plantarum, Lactobacillusfermentum, Lactobacillus acidophilus, 
Lactobacillus casei, Bifidobacterium bifidum,and Bifidobacterium longum.

In contrast to it, one of the most popular medicines to cure dysbacteriosis Acipol contains only Lactobacillus acidophilus.

Claimed benefits of this probiotic include the decrease of potentially pathogenic gastro-intestinal microorganisms and the strengthening of the immune system. Furthermore, L. plantarum и L. fermentum  improve bowel regularity.

The discovery can also be seen as a symbiotic, because beneficial microbiota is encased into polysaccharide carrier, which protects bacteria from deactivation in upper GIT and sustains its activity.

'Microbial population lies within the range of 10(8)-10(12) outdoing Linex and Acipol. The further increase of cells' amount will result only in escalated cost of the final product with the similar medicative activity' says Dina Yarullina, Head of the project, AP at KFU Department of Microbiology.

The results of the investigation were published in Molekulyarnaya Genetika, Mikrobiologiya i Virusologiya, Microbiology Journal, and Applied Biochemistry and Microbiology. The patent has been received and now the investors are sought for commercial implementation.